Microbial Metabolite-Mediated α-Synuclein Disaggregation
Target: SNCA, HSPA1A, DNMT1
Composite Score: 0.511
Price: $0.53▲15.0%
Citation Quality: Pending
neurodegeneration
Status: proposed
📄 Export → LaTeX
🟡 ALS / Motor Neuron Disease 🔴 Alzheimer's Disease 🔮 Lysosomal / Autophagy 🔥 Neuroinflammation 🟢 Parkinson's Disease 🧠 Neurodegeneration
✓ All Quality Gates Passed
Evidence Strength
Pending (0%)
22
Citations
1
Debates
5
Supporting
2
Opposing
Quality Report Card click to collapse
C+
Composite: 0.511
Top 65% of 1875 hypotheses
T5 Contested
Contradicted by evidence, under dispute
D
0.30
Top 97%
C
0.40
Top 78%
A
0.80
Top 25%
C+
0.50
Top 65%
B
0.60
Top 68%
C
0.40
Top 81%
B+
0.70
Top 22%
B
0.60
Top 56%
C
0.40
Top 89%
D
0.30
Top 91%
Evidence
5 supporting
|
2 opposing
Citation quality: 100%
Debates
2 sessions
B
Avg quality: 0.69
Convergence
1.00
A+
30 related hypothesis share this target
From Analysis:
What are the mechanisms underlying what are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesis through the gut-brain axis?
Description
Specific gut bacterial strains produce short-chain fatty acids (SCFAs) that cross the blood-brain barrier and directly modulate α-synuclein aggregation through epigenetic modifications of chaperone proteins. Therapeutic supplementation with SCFA-producing bacteria could prevent or reverse pathological protein aggregation in PD.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
graph TD
A["Gut Microbiome
B. longum, F. prausnitzii
A. muciniphila"] --> B["SCFA Production
Butyrate, Propionate
Acetate"]
B --> C["Blood-Brain Barrier
Crossing via MCT1/MCT2
Transporters"]
C --> D["HDAC Inhibition
HDAC1, HDAC3, HDAC6
Suppression"]
D --> E["Histone Hyperacetylation
H3/H4 Acetylation
Chromatin Remodeling"]
E --> F["HSF1/NF-Y Transcription
Factor Activation"]
F --> G["HSPA1A Upregulation
Heat Shock Protein 70
Expression"]
C --> H["DNMT1 Inhibition
DNA Methylation
Reduction"]
H --> I["Neuroprotective Gene
Demethylation"]
G --> J["Enhanced Protein
Chaperone Activity"]
I --> J
J --> K["alpha-Synuclein
Disaggregation"]
L["alpha-Synuclein
Pathological Aggregates"] --> K
K --> M["Reduced Neuronal
Toxicity"]
M --> N["Neuroprotection
Disease Modification"]
O["Therapeutic Intervention
SCFA Supplementation
Probiotic Administration"] --> B
GTEx v10 Brain Expression
JSONMedian TPM across 13 brain regions for SNCA, HSPA1A, DNMT1 from GTEx v10.
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
7 citations
7 with PMID
7 medium
Validation: 100%
5 supporting / 2 opposing
✓
For
(5)
(2)
Against
✗
High
Medium
Low
High
Medium
Low
Evidence Matrix
— sortable by strength/year, click Abstract to expand
Evidence Types
MECH 2CLIN 4GENE 1EPID 0
Legacy Card View — expandable citation cards
✓ Supporting Evidence 5
Targeting autophagy using small-molecule compounds to improve potential therapy of Parkinson's disease. MEDIUM
Recombinant pro-CTSD (cathepsin D) enhances SNCA/α-Synuclein degradation in α-Synucleinopathy models. MEDIUM
A ROS-Responsive nanoparticle for nuclear gene delivery and autophagy restoration in Parkinson's disease thera… MEDIUM▼
A ROS-Responsive nanoparticle for nuclear gene delivery and autophagy restoration in Parkinson's disease therapy.
Preclinical Alzheimer's disease shows alterations in circulating neuronal-derived extracellular vesicle microR… MEDIUM▼
Preclinical Alzheimer's disease shows alterations in circulating neuronal-derived extracellular vesicle microRNAs in a multiethnic cohort.
The Crosstalk Between Sepsis-Associated Encephalopathy and Alzheimer's Disease: Identifying Potential Biomarke… MEDIUM▼
The Crosstalk Between Sepsis-Associated Encephalopathy and Alzheimer's Disease: Identifying Potential Biomarkers and Therapeutic Targets for Cognition.
✗ Opposing Evidence 2
Short-chain fatty acids produced by gut microbiota promoted microglial activation and motor deficits in an alp… MEDIUM▼
Short-chain fatty acids produced by gut microbiota promoted microglial activation and motor deficits in an alpha-synuclein Parkinson model, contradicting a uniformly protective SCFA/disaggregation model.
Reviews of SCFAs, alpha-synuclein, neuroinflammation, and redox stress describe bidirectional and context-depe… MEDIUM▼
Reviews of SCFAs, alpha-synuclein, neuroinflammation, and redox stress describe bidirectional and context-dependent effects rather than direct disaggregation evidence.
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Hypothesis Debate | 4 rounds | 2026-04-27 | View Analysis
🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼
Theoretical Analysis: Microbial Inflammasome Priming Prevention
Key Molecular Mechanisms
The hypothesis integrates established components of the gut-brain axis with NLRP3 inflammasome biology. Pathogenic gut bacteria release damage-associated molecular patterns (DAMPs) and microbe-associated molecular patterns (MAMPs) that activate Toll-like receptor signaling in intestinal macrophages. This "priming signal" lowers the threshold for NLRP3 inflammasome assembly (NLRP3-PYCARD-CASP1 complex), enabling robust caspase-1 activation and subsequent IL-1β maturation and release (Bergsbaken et
🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼
Scientific Skeptic Evaluation
Foundational Weaknesses
Causal Direction Ambiguity: The hypothesis assumes gut bacteria → peripheral inflammation → neuroinflammation, but the reverse causality is equally plausible. Alpha-synuclein pathology may originate in the enteric nervous system, propagate via the vagus nerve, and cause gut barrier dysfunction as a consequence (Sampson et al., 2016). The proposed inflammatory cycle may be downstream, not upstream, of alpha-synuclein aggregation.
NLRP3 Specificity Unjustified: The hypothesis fixates on NLRP3 without excluding other inflam
🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼
Expert Assessment: Microbial Inflammasome Priming Prevention
Druggability
The NLRP3 inflammasome is a well-validated and druggable target with several clinical-stage compounds. MCC940 (NodThera/Novo Nordisk) completed Phase 1 for inflammatory disorders. DFV890 (dapansutrile, Novartis) completed Phase 2 trials (NCT04024888) for COVID-19 and gout, establishing human safety data. Both are oral small molecules with acceptable pharmacokinetics. The microbiome component is more challenging—FMT carries regulatory complexity, and probiotic strains lack standardization.
The dual-t
⚖ Synthesizer Integrates perspectives and produces final ranked assessments ▼
{"hypothesis_title": "Microbial Inflammasome Priming Prevention", "synthesis_summary": "This hypothesis proposes a compelling mechanistic link between gut dysbiosis and neurodegeneration via NLRP3 inflammasome priming, but faces significant challenges in establishing causal direction. While the dual-target strategy (inflammasome inhibition + microbiome restoration) leverages well-validated druggable targets like DFV890, the primary weakness is the unproven directionality of the gut-brain inflammatory cascade. The hypothesis may describe a downstream consequence of alpha-synuclein pathology r
Price History
7d Trend
↘
Falling
7d Momentum
▼ 19.9%
Volatility
High
0.0504
Events (7d)
4
⚡ Price Movement Log
Recent 15 events
| Event | Price | Change | Source | Time | |
|---|---|---|---|---|---|
| 📄 | New Evidence | $0.469 | ▲ 1.2% | evidence_batch_update | 2026-04-13 02:18 |
| 📄 | New Evidence | $0.464 | ▲ 3.5% | evidence_batch_update | 2026-04-13 02:18 |
| ⚖ | Recalibrated | $0.448 | ▼ 0.5% | 2026-04-12 10:15 | |
| ⚖ | Recalibrated | $0.450 | ▼ 1.2% | 2026-04-10 15:58 | |
| ⚖ | Recalibrated | $0.456 | ▲ 1.5% | 2026-04-10 15:53 | |
| ⚖ | Recalibrated | $0.449 | ▼ 3.8% | 2026-04-08 18:39 | |
| ⚖ | Recalibrated | $0.467 | ▼ 12.9% | 2026-04-06 04:04 | |
| ⚖ | Recalibrated | $0.536 | ▼ 0.6% | 2026-04-04 16:38 | |
| ⚖ | Recalibrated | $0.539 | ▼ 0.4% | 2026-04-04 16:02 | |
| 📄 | New Evidence | $0.542 | ▲ 0.7% | evidence_batch_update | 2026-04-04 09:08 |
| ⚖ | Recalibrated | $0.538 | ▼ 2.0% | 2026-04-03 23:46 | |
| ⚖ | Recalibrated | $0.549 | ▼ 5.6% | 2026-04-02 21:55 | |
| 💬 | Debate Round | $0.581 | ▲ 34.1% | market_dynamics | 2026-04-02 19:41 |
| ⚖ | Recalibrated | $0.433 | ▼ 2.5% | market_recalibrate | 2026-04-02 19:14 |
| 📄 | New Evidence | $0.444 | ▼ 41.2% | market_dynamics_seed | 2026-04-02 18:16 |
Clinical Trials (5) Relevance: 44%
0
Active
Active
0
Completed
Completed
282
Total Enrolled
Total Enrolled
PHASE1
Highest Phase
Highest Phase
RAPA-501 Therapy for ALS
PHASE2
RECRUITING
·
NCT04220190 · Rapa Therapeutics LLC
41 enrolled · 2025-01-02 · → 2026-07-01
RAPA-501-ALS is a phase 2/3 expansion cohort study of RAPA-501 autologous hybrid TREG/Th2 cells in patients living with amyotrophic lateral sclerosis (pwALS).
Amyotrophic Lateral Sclerosis
RAPA-501 Autologous T stem cells
COMPLETED
·
NCT03955380 · Prof. Dr. Dieter Willbold
24 enrolled · 2018-12-12 · → 2019-04-03
This is a single-center multiple-ascending-dose clinical trial assessing the safety and tolerability of oral dosing of Contraloid acetate in healthy volunteers. The study drug Contraloid (alias RD2, a
Alzheimer Dementia Alzheimer Disease
Contraloid
UNKNOWN
·
NCT04820881 · Washington D.C. Veterans Affairs Medical Center
60 enrolled · 2021-10-01 · → 2024-09
This grant award entitled, "Cerebrovascular Reactivity and Oxygen Metabolism as Markers for Neurodegeneration after Traumatic Brain Injury" (hereafter, "Neurovascular Study"), aims to determine if neu
Neurodegenerative Diseases
Stereotactic Intracerebral Injection of Allogenic IPSC-DAPs in Patients With Parkinson's Disease
PHASE1
NOT_YET_RECRUITING
·
NCT07212088 · iCamuno Biotherapeutics Ltd.
12 enrolled · 2026-02-28 · → 2027-12-15
Parkinson's disease is a progressive neurodegenerative disorder characterized by high morbidity due to the limited regenerative capacity of dopaminergic neurons in the brain. Current drug treatments p
Parkinson Disease
ALC01 therapy
COMPLETED
·
NCT02405182 · University of Alberta
145 enrolled · 2014-09 · → 2019-03
Amyotrophic lateral sclerosis (ALS) is a disabling and rapidly progressive neurodegenerative disorder. There is no treatment that significantly slows progression. Increasing age is an important risk f
Amyotrophic Lateral Sclerosis ALS Motor Neuron Diseases
Magnetic Resonance Imaging
📚 Cited Papers (39)
Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature.
Movement disorders : official journal of the Movement Disorder Society (2017) · PMID:29124790
1 figure
Figures
Figures available at source paper (no open-access XML found).
deep_link
Small molecule-driven NLRP3 inflammation inhibition via interplay between ubiquitination and autophagy: implications for Parkinson disease.
Autophagy (2020) · PMID:30966861
1 figure
Figures
Figures available at source paper (no open-access XML found).
deep_link
Alpha-synuclein, Parkinson's disease, and Alzheimer's disease.
Parkinsonism & related disorders (2004) · PMID:15109581
No extracted figures yet
Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson's Disease.
Cell (2017) · PMID:27912057
No extracted figures yet
Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature.
Movement disorders : official journal of the Movement Disorder Society (2017) · PMID:29124790
No extracted figures yet
Small molecule-driven NLRP3 inflammation inhibition via interplay between ubiquitination and autophagy: implications for Parkinson disease.
Autophagy (2020) · PMID:30966861
No extracted figures yet
Transneuronal Propagation of Pathologic α-Synuclein from the Gut to the Brain Models Parkinson's Disease.
Neuron (2019) · PMID:31255487
No extracted figures yet
Kv1.3 modulates neuroinflammation and neurodegeneration in Parkinson's disease.
J Clin Invest (2020) · PMID:32597830
No extracted figures yet
Mitochondria and Parkinson's Disease: Clinical, Molecular, and Translational Aspects.
Journal of Parkinson's disease (2021) · PMID:33074190
No extracted figures yet
The Role of α-Synuclein Oligomers in Parkinson's Disease.
International journal of molecular sciences (2020) · PMID:33212758
No extracted figures yet
Mitochondrial Dysfunction and Mitophagy in Parkinson's Disease: From Mechanism to Therapy.
Trends in biochemical sciences (2021) · PMID:33323315
No extracted figures yet
The role of neuroimaging in Parkinson's disease.
J Neurochem (2021) · PMID:34532856
No extracted figures yet
📅 Citation Freshness Audit
Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.
No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.
📙 Related Wiki Pages (15)
NES Protein proteinPBKR03 entitySNCA — Alpha-Synuclein geneDNMT1 Gene geneHSPA1A Gene geneHSPA1A Protein proteinSNCA — Alpha-Synuclein Gene Entity Page geneExosome Therapy for Neurodegeneration therapeuticArcuate NPY Neurons in Neurodegeneration cellPhotoreceptors in Neurodegeneration cellEconomic Burden — Neurodegeneration diseaseGlucocorticoid Signaling Pathway in Neurodegenerat mechanismLipid Raft Dysfunction in Neurodegeneration mechanismRaphe Serotonergic Neurons in Neurodegeneration cellPET Imaging in Neurodegeneration diagnostic
📓 Linked Notebooks (5)
📓 SciDEX Analysis: 2026 04 01 Gap 20260401 225155
Computational notebook for SDA-2026-04-01-gap-20260401-225155
📓 What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesis through the gut-brain axis? — Rich Analysis
Enhanced notebook with gene expression, pathway enrichment, score heatmaps, and statistical analysis. What are the mechanisms underlying what are the mechanisms by which gut microbiome dysbiosis influ …
📓 Gut microbiome dysbiosis and Parkinsons disease -- Rich Analysis Notebook
Gene expression, pathway enrichment, statistical tests for: Gut microbiome dysbiosis and Parkinsons disease
📓 What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesis through the gut-brain axis?
What are the mechanisms underlying what are the mechanisms by which gut microbiome dysbiosis influences parkinson's disease pathogenesis through the gut-brain axis??
📓 What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesis through the gut-brain axis?
What are the mechanisms underlying what are the mechanisms by which gut microbiome dysbiosis influences parkinson's disease pathogenesis through the gut-brain axis??
📊 Resource Economics & ROI
Low Efficiency
Resource Efficiency Score
0.49
24.9th percentile (776 hypotheses)
Tokens Used
20,466
KG Edges Generated
17
Citations Produced
22
Cost Ratios
Cost per KG Edge
40.53 tokens
Lower is better (baseline: 2000)
Cost per Citation
1279.12 tokens
Lower is better (baseline: 1000)
Cost per Score Point
37483.52 tokens
Tokens / composite_score
Score Impact
Efficiency Boost to Composite
+0.049
10% weight of efficiency score
Adjusted Composite
0.560
How Economics Pricing Works
Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.
High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.
Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.
Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.
Efficiency Price Signals
| Date | Signal Price | Score |
|---|---|---|
| 2026-04-16T20:00 | $0.463 | 0.580 |
📋 Reviews View all →
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
💬 Discussion
No DepMap CRISPR Chronos data found for SNCA, HSPA1A, DNMT1.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
Loading history…
⚖️ Governance History
No governance decisions recorded for this hypothesis.
Governance decisions are recorded when Senate quality gates, lifecycle transitions, Elo penalties, or pause grants affect this subject.
Wiki Pages
NES ProteinproteinPBKR03entitySNCA — Alpha-SynucleingeneDNMT1 GenegeneHSPA1A GenegeneHSPA1A ProteinproteinSNCA — Alpha-Synuclein Gene Entity PagegeneExosome Therapy for NeurodegenerationtherapeuticArcuate NPY Neurons in NeurodegenerationcellPhotoreceptors in NeurodegenerationcellEconomic Burden — NeurodegenerationdiseaseGlucocorticoid Signaling Pathway in NeurodegeneratmechanismLipid Raft Dysfunction in NeurodegenerationmechanismRaphe Serotonergic Neurons in NeurodegenerationcellPET Imaging in Neurodegenerationdiagnostic
KG Entities (14)
GLP1_receptorNLRP3Parkinsons_diseaseSCFA_productionblood_brain_barriergut_microbiomeinflammasome_complexintestinal_barrierneuroinflammation_pathwayneuroprotectionprocessedsess_SDA-2026-04-01-gap-20260401-225155tight_junction_proteinsvagal_signaling_pathway
Dependency Graph (7 upstream, 1 downstream)
Depends On
Enteric Nervous System Prion-Like Propagation Blockadebuilds_on (1.0)Smartphone-Detected Motor Variability Correctionbuilds_on (1.0)Gut Barrier Permeability-α-Synuclein Axis Modulationbuilds_on (1.0)Noradrenergic-Tau Propagation Blockadebuilds_on (1.0)Cross-Seeding Prevention Strategybuilds_on (1.0)Low Complexity Domain Cross-Linking Inhibitionbuilds_on (0.6)Mitochondrial Transfer Pathway Enhancementbuilds_on (0.6)Linked Experiments (10)
Iron Dyshomeostasis in MSA Pathogenesis Experimentvalidation | tests | 0.40Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiation Mechanismsclinical | tests | 0.40Gut-Brain Axis Pathogenesis in Parkinson's Disease — Mechanism and Interventionclinical | tests | 0.40Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propagationclinical | tests | 0.40Stress Granule Dysfunction Validation in Parkinson's Diseaseclinical | tests | 0.40Tau Co-Pathology in DLB Clinical Heterogeneityclinical | tests | 0.40Prodromal Parkinson's Disease Biomarker Development — Early Detection for Prevenclinical | tests | 0.40Alpha-Synuclein SAA Kinetics Study — Biological Staging Backbone for PD Progressclinical | tests | 0.40Parkinson's Disease Subtype Classification — Precision Medicine Approachclinical | tests | 0.40Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleationvalidation | tests | 0.40
Related Hypotheses
Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming in Neurodegeneration
Score: 0.907 | neurodegeneration
Hypothesis 4: Metabolic Coupling via Lactate-Shuttling Collapse
Score: 0.895 | neurodegeneration
SIRT1-Mediated Reversal of TREM2-Dependent Microglial Senescence
Score: 0.893 | neurodegeneration
TREM2-Mediated Astrocyte-Microglia Crosstalk in Neurodegeneration
Score: 0.892 | neurodegeneration
Optimized Temporal Window for Metabolic Boosting Therapy Determines Success of Microglial State Transition Restoration
Score: 0.887 | neurodegeneration
Estimated Development
Estimated Cost
$0
Timeline
2.2 years
🧪 Falsifiable Predictions (2)
2 total
0 confirmed
0 falsified
If hypothesis is true, intervention incorporate engineered bacterial strains with enhanced SCFA production capacity and targeted delivery mechanisms, including synthetic biology approaches to optimize butyrate biosynthetic pathways
pending
conf: 0.40
Expected outcome: incorporate engineered bacterial strains with enhanced SCFA production capacity and targeted delivery mechanisms, including synthetic biology approaches to optimize butyrate biosynthetic pathways
Falsified by: Intervention fails to incorporate engineered bacterial strains with enhanced SCFA production capacity and targeted delivery mechanisms, including synthetic biology approaches to optimize butyrate biosynthetic pathways
If hypothesis is true, intervention integrate pharmacogenomic profiling, microbiome analysis, and metabolomic signatures to optimize strain selection and dosing for individual patients
pending
conf: 0.40
Expected outcome: integrate pharmacogenomic profiling, microbiome analysis, and metabolomic signatures to optimize strain selection and dosing for individual patients
Falsified by: Intervention fails to integrate pharmacogenomic profiling, microbiome analysis, and metabolomic signatures to optimize strain selection and dosing for individual patients
Knowledge Subgraph (8 edges)
associated with (2)
causal extracted (1)
contributes to (1)
encodes component (1)
maintains (1)
mediates (1)
promotes (1)
Mechanism Pathway for SNCA, HSPA1A, DNMT1
Molecular pathway showing key causal relationships underlying this hypothesis
graph TD
NLRP3["NLRP3"] -->|encodes component| inflammasome_complex["inflammasome_complex"]
neuroinflammation_pathway["neuroinflammation_pathway"] -->|contributes to| Parkinsons_disease["Parkinsons_disease"]
GLP1_receptor["GLP1_receptor"] -->|mediates| vagal_signaling_pathway["vagal_signaling_pathway"]
tight_junction_proteins["tight_junction_proteins"] -->|maintains| intestinal_barrier["intestinal_barrier"]
gut_microbiome["gut_microbiome"] -->|associated with| SCFA_production["SCFA_production"]
SCFA_production_1["SCFA_production"] -->|associated with| blood_brain_barrier["blood_brain_barrier"]
vagal_signaling_pathway_2["vagal_signaling_pathway"] -->|promotes| neuroprotection["neuroprotection"]
sess_SDA_2026_04_01_gap_2["sess_SDA-2026-04-01-gap-20260401-225155"] -->|causal extracted| processed["processed"]
style NLRP3 fill:#ce93d8,stroke:#333,color:#000
style inflammasome_complex fill:#4fc3f7,stroke:#333,color:#000
style neuroinflammation_pathway fill:#81c784,stroke:#333,color:#000
style Parkinsons_disease fill:#ef5350,stroke:#333,color:#000
style GLP1_receptor fill:#4fc3f7,stroke:#333,color:#000
style vagal_signaling_pathway fill:#81c784,stroke:#333,color:#000
style tight_junction_proteins fill:#4fc3f7,stroke:#333,color:#000
style intestinal_barrier fill:#4fc3f7,stroke:#333,color:#000
style gut_microbiome fill:#4fc3f7,stroke:#333,color:#000
style SCFA_production fill:#4fc3f7,stroke:#333,color:#000
style SCFA_production_1 fill:#4fc3f7,stroke:#333,color:#000
style blood_brain_barrier fill:#4fc3f7,stroke:#333,color:#000
style vagal_signaling_pathway_2 fill:#81c784,stroke:#333,color:#000
style neuroprotection fill:#4fc3f7,stroke:#333,color:#000
style sess_SDA_2026_04_01_gap_2 fill:#4fc3f7,stroke:#333,color:#000
style processed fill:#4fc3f7,stroke:#333,color:#000
3D Protein Structure
🧬 SNCA — PDB 1XQ8 Click to expand 3D viewer
Source Analysis
What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesis through the gut-brain axis?
neurodegeneration | 2026-04-01 | completed
Community Feedback
0
0 upvotes · 0 downvotes
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
Same Analysis (5)
Microbial Inflammasome Priming Prevention
Score: 0.65 · NLRP3, CASP1, IL1B, PYCARD
Vagal Afferent Microbial Signal Modulation
Score: 0.62 · GLP1R, BDNF
Gut Barrier Permeability-α-Synuclein Axis Modulation
Score: 0.53 · CLDN1, OCLN, ZO1, MLCK
Enteric Nervous System Prion-Like Propagation Blockade
Score: 0.48 · TLR4, SNCA
Microbiome-Derived Tryptophan Metabolite Neuroprotection
→ View all analysis hypotheses
Score: 0.43 · AHR, IL10, TGFB1